RJA
ARQT icon

Raymond James & Associates’s Arcutis Biotherapeutics ARQT Stock Holding History

Raymond James & Associates’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-21,631
Closed -$201K – 3995
2024
Q2 		$201K Sell
21,631
-19,811
-48% -$179K ﹤0.01% 3600
2024
Q1 		$411K Buy
+41,442
New +$309K ﹤0.01% 3188

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates's ARQT Position: Q3 2024 in Review

Raymond James & Associates sold out of Arcutis Biotherapeutics (ARQT) in Q3 2024, closing a stake of 21,631 shares — an estimated $201K sold.

Raymond James & Associates first reported a position in ARQT in Q1 2024 and held it in 2 quarters. The position peaked at $411K in Q1 2024. 188 funds tracked by Wall St. Rank hold ARQT as of Q3 2024.

  • Raymond James & Associates reported no remaining Arcutis Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Raymond James & Associates sold 21,631 Arcutis Biotherapeutics shares in Q3 2024, an estimated $201K.
  • Raymond James & Associates first reported a position in Arcutis Biotherapeutics in Q1 2024 and held it in 2 quarters.
  • Raymond James & Associates's Arcutis Biotherapeutics position peaked at $411K in Q1 2024.
  • 188 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.